The present invention provides stable amorphous calcium carbonate (ACC) compositions, and food articles comprising said compositions.

The present invention provides stable amorphous calcium carbonate (ACC) compositions, and food articles comprising said compositions.

Our invention is a mixture of carboxylic acids: citric acid, succinic acid, fumaric acid and malic acid, and any possible combinations thereof. This product is used orally or also intravenously, in the treatment of patients with chronic renal failure, hyperammonemia or human conditions having negative nitrogen balance. This product is beneficial in decreasing the serum values of urea and serum ammonium, while promoting by transamination of the oxalacetate formed via succinate, fumarate and malate, the biosynthesis of non-essential amino acids; by transamination of the alpha ketoglutarate formed via citrate, it generates glutamic acid and related amino acids such as glutamine. This treatment prevents, preserves and even improves kidney function. In other patients it delays deterioration of renal function and the urgent need for renal replacement therapy. In others, it is used as a supplemental renal replacement treatment to improve the patient's quality of life and improve laboratory parameters.

Our invention is a mixture of carboxylic acids: citric acid, succinic acid, fumaric acid and malic acid, and any possible combinations thereof. This product is used orally or also intravenously, in the treatment of patients with chronic renal failure, hyperammonemia or human conditions having negative nitrogen balance. This product is beneficial in decreasing the serum values of urea and serum ammonium, while promoting by transamination of the oxalacetate formed via succinate, fumarate and malate, the biosynthesis of non-essential amino acids; by transamination of the alpha ketoglutarate formed via citrate, it generates glutamic acid and related amino acids such as glutamine. This treatment prevents, preserves and even improves kidney function. In other patients it delays deterioration of renal function and the urgent need for renal replacement therapy. In others, it is used as a supplemental renal replacement treatment to improve the patient's quality of life and improve laboratory parameters.

Our invention is a mixture of carboxylic acids: citric acid, succinic acid, fumaric acid and malic acid, and any possible combinations thereof. This product is used orally or also intravenously, in the treatment of patients with chronic renal failure, hyperammonemia or human conditions having negative nitrogen balance. This product is beneficial in decreasing the serum values of urea and serum ammonium, while promoting by transamination of the oxalacetate formed via succinate, fumarate and malate, the biosynthesis of non-essential amino acids; by transamination of the alpha ketoglutarate formed via citrate, it generates glutamic acid and related amino acids such as glutamine. This treatment prevents, preserves and even improves kidney function. In other patients it delays deterioration of renal function and the urgent need for renal replacement therapy. In others, it is used as a supplemental renal replacement treatment to improve the patient's quality of life and improve laboratory parameters.

The present disclosure relates to a herbo-mineral metallic pharmaceutical kit and a process for its preparation. The herbo-mineral metallic pharmaceutical kit comprises Suvarna Bhasmadi Vati (SBV), Mouktikyukta Kamdudha Vati (MKV), Trailokyachintamani Rasa Vati (TCR), Kumari Kalpa Vati (KKV) and Khadirarishta (KHA). The herbo-mineral metallic pharmaceutical kit of the present disclosure can be used for delaying and/or controlling the recurrence or occurrence of breast and/or ovarian cancer in second breast and/or ovary or metastasis. The herbo-mineral metallic pharmaceutical compositions of the kit assist in reducing oxidative stress, improving immune status and quality of life and maintaining a disease-free survival in patients who are genetically predisposed to breast or ovarian cancer.

The present disclosure relates to a herbo-mineral metallic pharmaceutical kit and a process for its preparation. The herbo-mineral metallic pharmaceutical kit comprises Suvarna Bhasmadi Vati (SBV), Mouktikyukta Kamdudha Vati (MKV), Trailokyachintamani Rasa Vati (TCR), Kumari Kalpa Vati (KKV) and Khadirarishta (KHA). The herbo-mineral metallic pharmaceutical kit of the present disclosure can be used for delaying and/or controlling the recurrence or occurrence of breast and/or ovarian cancer in second breast and/or ovary or metastasis. The herbo-mineral metallic pharmaceutical compositions of the kit assist in reducing oxidative stress, improving immune status and quality of life and maintaining a disease-free survival in patients who are genetically predisposed to breast or ovarian cancer.

Composite materials made of a citrate, a calcium carbonate-containing material and an association moiety which is associated with the citrate and the calcium carbonate-containing material are provided. The composite materials are typically particulate materials (e.g., powdery materials). Compositions and articles-of-manufacturing containing and/or configured for applying the composite materials are also provided, as well as their use in inducing blood coagulation and arresting hemorrhage, including internal and/or massive hemorrhage.

Composite materials made of a citrate, a calcium carbonate-containing material and an association moiety which is associated with the citrate and the calcium carbonate-containing material are provided. The composite materials are typically particulate materials (e.g., powdery materials). Compositions and articles-of-manufacturing containing and/or configured for applying the composite materials are also provided, as well as their use in inducing blood coagulation and arresting hemorrhage, including internal and/or massive hemorrhage.

One compound (100) according to the present invention contains silicon fine particles having a capability of generating hydrogen or aggregates of the silicon fine particles. The compound that contains the silicon fine particles or the aggregates having a capability of generating hydrogen is capable of generating hydrogen in the body of, for example, an animal that has ingested the compound. For a plant, the compound can be disposed or charged into, for example, moisture (water-containing liquid) or fertilizer to be provided to the plant, to supply the plant with hydrogen generated from the compound.